Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
News Jun 19, 2012
Cobra Biologics and Alligator Bioscience AB have announced that they have entered into a manufacturing services and supply agreement for the production of monoclonal antibody Drug Substance and Drug Product for pre-clinical studies and Phase I-II clinical trials.
Under the terms of the agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.
Peter Coleman, CEO of Cobra Biologics said: "Having been through a rigorous selection process, we are very pleased to have been chosen by Alligator. We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility (Sweden) enabled us to win this important program with Alligator in a highly competitive market place. We look forward to building a lasting relationship with Alligator Bioscience.”
Alligator will be taking advantage of Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello™ robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE